Does the media prefer BMY or RPRX?

In the previous week, Bristol Myers Squibb had 41 more articles in the media than Royalty Pharma. MarketBeat recorded 49 mentions for Bristol Myers Squibb and 8 mentions for Royalty Pharma. Bristol Myers Squibb's average media sentiment score of 1.30 beat Royalty Pharma's score of 0.47 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 35 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation and earnings, RPRX or SNY?

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.38B 15.45 $770.95M $1.45 44.06 Sanofi $49.35B 2.18 $8.84B $1.91 23.21

Is RPRX or SNY more profitable?

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 32.14% 30.01% 14.91% Sanofi 8.66% 14.19% 7.95%

Does the media refer more to RPRX or SNY?

In the previous week, Royalty Pharma had 4 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for Royalty Pharma and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.56 beat Royalty Pharma's score of 0.47 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, RPRX or GSK?

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.38B 15.45 $770.95M $1.45 44.06 GSK $43.07B 2.39 $7.54B $3.20 15.90

Is RPRX or GSK more profitable?

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 32.14% 30.01% 14.91% GSK 14.56% 43.23% 11.60%

Does the media refer more to RPRX or GSK?

In the previous week, GSK had 2 more articles in the media than Royalty Pharma. MarketBeat recorded 10 mentions for GSK and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.47 beat GSK's score of 0.17 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TAK or RPRX?

Royalty Pharma has a consensus target price of $60.86, indicating a potential downside of 4.73%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor TAK or RPRX?

In the previous week, Royalty Pharma had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Royalty Pharma and 4 mentions for Takeda Pharmaceutical. Royalty Pharma's average media sentiment score of 0.47 beat Takeda Pharmaceutical's score of 0.45 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to RPRX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 8 mentions for Royalty Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.93 beat Royalty Pharma's score of 0.47 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 12 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Royalty Pharma (RPRX) Competitors

$63.88 +0.77 (+1.22%)

As of 09/3/2026 04:00 PM Eastern

Compare

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

Should you buy Royalty Pharma stock or one of its competitors? Royalty Pharma's main competitors and comparable companies include Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Bristol Myers Squibb has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bristol Myers Squibb currently has a consensus target price of $66.06, suggesting a potential downside of 2.95%. Royalty Pharma has a consensus target price of $60.86, suggesting a potential downside of 4.73%. Given Bristol Myers Squibb's higher probable upside, analysts plainly believe Bristol Myers Squibb is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Bristol Myers Squibb's net margin of 18.87%. Bristol Myers Squibb's return on equity of 66.90% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Royalty Pharma	32.14%	30.01%	14.91%

Bristol Myers Squibb has higher revenue and earnings than Royalty Pharma. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.88	$7.05B	$4.54	14.99
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.7%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Royalty Pharma has increased its dividend for 5 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Bristol Myers Squibb had 41 more articles in the media than Royalty Pharma. MarketBeat recorded 49 mentions for Bristol Myers Squibb and 8 mentions for Royalty Pharma. Bristol Myers Squibb's average media sentiment score of 1.30 beat Royalty Pharma's score of 0.47 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	35 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Bristol Myers Squibb beats Royalty Pharma on 13 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Sanofi?

Royalty Pharma (NASDAQ:RPRX) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Sanofi	8.66%	14.19%	7.95%

In the previous week, Royalty Pharma had 4 more articles in the media than Sanofi. MarketBeat recorded 8 mentions for Royalty Pharma and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.56 beat Royalty Pharma's score of 0.47 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma has increased its dividend for 5 consecutive years.

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06
Sanofi	$49.35B	2.18	$8.84B	$1.91	23.21

Royalty Pharma presently has a consensus price target of $60.86, indicating a potential downside of 4.73%. Sanofi has a consensus price target of $49.50, indicating a potential upside of 11.66%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Royalty Pharma has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Summary

Royalty Pharma beats Sanofi on 13 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to GSK?

Royalty Pharma (NASDAQ:RPRX) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06
GSK	$43.07B	2.39	$7.54B	$3.20	15.90

Royalty Pharma currently has a consensus price target of $60.86, indicating a potential downside of 4.73%. GSK has a consensus price target of $53.00, indicating a potential upside of 4.17%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
GSK	14.56%	43.23%	11.60%

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, GSK had 2 more articles in the media than Royalty Pharma. MarketBeat recorded 10 mentions for GSK and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.47 beat GSK's score of 0.17 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. GSK pays an annual dividend of $1.78 per share and has a dividend yield of 3.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. GSK pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Royalty Pharma beats GSK on 11 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma has a consensus target price of $60.86, indicating a potential downside of 4.73%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Takeda Pharmaceutical's net margin of 3.80%. Royalty Pharma's return on equity of 30.01% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Royalty Pharma	32.14%	30.01%	14.91%

In the previous week, Royalty Pharma had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Royalty Pharma and 4 mentions for Takeda Pharmaceutical. Royalty Pharma's average media sentiment score of 0.47 beat Takeda Pharmaceutical's score of 0.45 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.5%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 5 consecutive years.

Royalty Pharma has lower revenue, but higher earnings than Takeda Pharmaceutical. Royalty Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.12	-$1.01B	$0.34	55.03
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06

Summary

Royalty Pharma beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Royalty Pharma (NASDAQ:RPRX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Royalty Pharma presently has a consensus price target of $60.86, indicating a potential downside of 4.73%. Teva Pharmaceutical Industries has a consensus price target of $42.22, indicating a potential upside of 15.42%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	15.45	$770.95M	$1.45	44.06
Teva Pharmaceutical Industries	$17.26B	2.47	$1.41B	$0.60	60.97

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Royalty Pharma has a net margin of 32.14% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 8 mentions for Royalty Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.93 beat Royalty Pharma's score of 0.47 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	12 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Royalty Pharma on 9 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.29B	$12.25B	$7.26B	$12.73B
Dividend Yield	1.49%	2.59%	2.53%	8.86%
P/E Ratio	44.06	787.27	273.29	25.38
Price / Sales	15.45	753.79	613.45	92.55
Price / Cash	13.21	94.80	77.82	52.26
Price / Book	3.75	12.33	12.89	6.14
Net Income	$770.95M	$2.82B	$3.47B	$349.01M
7 Day Performance	4.98%	2.59%	0.60%	-0.27%
1 Month Performance	11.13%	6.95%	5.73%	0.68%
1 Year Performance	73.12%	9.45%	25.35%	14.84%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	3.3979 of 5 stars	$63.88 +1.2%	$60.86 -4.7%	+74.2%	$36.29B	$2.38B	44.06	80
BMY Bristol Myers Squibb	4.7223 of 5 stars	$66.93 +0.5%	$66.06 -1.3%	+43.4%	$136.00B	$48.19B	14.74	32,500	Trending News
SNY Sanofi	3.2532 of 5 stars	$44.36 -1.0%	$49.50 +11.6%	-11.1%	$108.66B	$49.35B	23.23	74,846
GSK GSK	3.0782 of 5 stars	$50.29 -1.0%	$53.00 +5.4%	+29.3%	$102.79B	$43.07B	15.73	66,841	News Coverage Dividend Cut Gap Up
TAK Takeda Pharmaceutical	1.4426 of 5 stars	$18.00 -0.2%	N/A	+23.5%	$57.77B	$28.32B	52.94	47,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Summary

How does Royalty Pharma compare to Sanofi?

Summary

How does Royalty Pharma compare to GSK?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, SNY, GSK, TAK, and TEVA

How does Royalty Pharma compare to Bristol Myers Squibb?

Which has more risk and volatility, BMY or RPRX?

Do insiders and institutionals believe in BMY or RPRX?

Do analysts rate BMY or RPRX?

Is BMY or RPRX more profitable?

Which has stronger valuation & earnings, BMY or RPRX?

Is BMY or RPRX a better dividend stock?

Does the media prefer BMY or RPRX?

Summary

How does Royalty Pharma compare to Sanofi?

Is RPRX or SNY more profitable?

Does the media refer more to RPRX or SNY?

Do insiders & institutionals have more ownership in RPRX or SNY?

Is RPRX or SNY a better dividend stock?

Which has higher valuation and earnings, RPRX or SNY?

Do analysts recommend RPRX or SNY?

Which has more volatility and risk, RPRX or SNY?

Summary

How does Royalty Pharma compare to GSK?

Which has better earnings and valuation, RPRX or GSK?

Do analysts recommend RPRX or GSK?

Is RPRX or GSK more profitable?

Do institutionals and insiders believe in RPRX or GSK?

Does the media refer more to RPRX or GSK?

Which has more volatility and risk, RPRX or GSK?

Is RPRX or GSK a better dividend stock?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Do institutionals and insiders believe in TAK or RPRX?

Do analysts prefer TAK or RPRX?

Is TAK or RPRX more profitable?

Does the media favor TAK or RPRX?

Which has more volatility & risk, TAK or RPRX?

Is TAK or RPRX a better dividend stock?

Which has higher earnings and valuation, TAK or RPRX?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Do analysts prefer RPRX or TEVA?

Which has better earnings and valuation, RPRX or TEVA?

Do insiders and institutionals believe in RPRX or TEVA?

Is RPRX or TEVA more profitable?

Does the media refer more to RPRX or TEVA?

Which has more risk & volatility, RPRX or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools